SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Lupin recalls 43,860 bottles of ophthalmic solution in US

22 Feb 2019 Evaluate

Lupin is recalling 43,860 bottles of Moxifloxacin Ophthalmic solution, used to treat bacterial conjunctivitis, in the US market. The US health regulator, United States Food and Drug Administration (USFDA) has classified it as a class-III recall, which is initiated in a situation in which use of or exposure to a violative product is not likely to cause adverse health consequences.

According to USFDA, the product was distributed by five wholesalers, six drug chains, four mail order pharmacies and one mail order pharmacy or supermarket, who may have further distributed it throughout the US.

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.

Lupin Share Price

2300.00 -11.75 (-0.51%)
22-Apr-2026 15:52 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1669.50
Dr. Reddys Lab 1216.60
Cipla 1235.00
Zydus Lifesciences 928.00
Lupin 2300.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×